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Background: Inborn enzyme defects of mitochondrial fatty acid beta-oxidation (FAO) form a large group of genetic
disorders associated to variable clinical presentations ranging from life-threatening pediatric manifestations up to
milder late onset phenotypes, including myopathy. Very few candidate drugs have been identified in this group of
disorders. Resveratrol (RSV) is a natural polyphenol with anti-oxidant and anti-inflammatory effects, recently shown
to have beneficial metabolic properties in mice models. Our study explores its possible effects on FAO and
mitochondrial energy metabolism in human cells, which are still very little documented.
Methods: Using cells from controls and from patients with Carnitine Palmitoyl Transferase 2 (CPT2) or Very Long
Chain AcylCoA Dehydrogenase (VLCAD) deficiency we characterized the metabolic effects of RSV, RSV metabolites,
and other stilbenes. We also focused on analysis of RSV uptake, and on the effects of low RSV concentrations,
considering the limited bioavailability of RSV in vivo.
Results: Time course of RSV accumulation in fibroblasts over 48 h of treatment were consistent with the resulting
stimulation or correction of FAO capacities. At 48 h, half maximal and maximal FAO stimulations were respectively
achieved for 37,5 microM (EC50) and 75 microM RSV, but we found that serum content of culture medium
negatively modulated RSV uptake and FAO induction. Indeed, decreasing serum from 12% to 3% led to shift EC50
from 37,5 to 13 microM, and a 2.6-3.6-fold FAO stimulation was reached with 20 microM RSV at 3% serum, that
was absent at 12% serum. Two other stilbenes often found associated with RSV, i.e. cis- RSV and piceid, also
triggered significant FAO up-regulation. Resveratrol glucuro- or sulfo- conjugates had modest or no effects. In
contrast, dihydro-RSV, one of the most abundant circulating RSV metabolites in human significantly stimulated FAO
(1.3-2.3-fold).
Conclusions: This study provides the first compared data on mitochondrial effects of resveratrol, its metabolites,
and other natural compounds of the stilbene family in human cells. The results clearly indicate that several of these
compounds can improve mitochondrial FAO capacities in human FAO-deficient cells.
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Resveratrol (RSV) or trans-3, 4′, 5-trihydroxystilbene is a
natural polyphenol of the stilbene family produced by
plants in response to environmental stress, which is found
in different fruits (red grape, berries, peanuts, etc.…) and in
plant-based foods, in particular in red wine. RSV was ini-
tially shown to exhibit anti-oxidant, anti-inflammatory, and
anti-proliferative effects in various cell systems, with poten-
tial applications in cancer and cardiovascular diseases [1-3].
More recent studies established that dietary supplemen-
tation with relatively high doses of RSV could provide
resistance to obesity, and improve muscular performance,
in mice fed a high-fat diet, whereas these effects were not
observed at lower doses of RSV [4,5]. This raised the hy-
pothesis that RSV could impact mitochondrial energy me-
tabolism. In line with this, other data suggest that, at least
in some metabolically compromised states, RSV supple-
mentation might modulate mitochondrial functions in
liver, skeletal muscle, or adipose tissue [6,7].
Chronic in vivo administration of RSV for long periods
of time might variably affect many enzymes and metabolic
pathways, through direct or indirect mechanisms. Accord-
ingly, delineating the mitochondrial response to RSV re-
quires ex vivo studies in cell models. There are yet limited
data suggesting that treatment with RSV could impact
mitochondrial fatty acid ß-oxidation [5,8-10] or oxida-
tive phosphorylation in cultured cells [10]. These ef-
fects of RSV might find applications for the treatment
of various diseases involving mitochondrial dysfunc-
tions, such as diabetes, cardiovascular or neurodegener-
ative disorders [2].
Carnitine Palmitoyltransferase 2 (CPT2) and Very Long
Chain AcylCoA Dehydrogenase (VLCAD) deficiencies
belong to a group of more than fifteen genetic dis-
eases affecting one of the enzymes of the mitochondrial
ß-oxidation pathway, well characterized at the clinical
and molecular levels, but for which treatments remain
quite limited [11,12]. A wide panel of mutations is en-
countered in these disorders, and a majority of patients
harbor missense mutations compatible with the pro-
duction of unstable variant enzymes with very low re-
sidual activity. This results in a significant reduction in
the capacity to use long-chain fatty acids as energy sub-
strate, as typically observed in fibroblasts from patients
with the myopathic form of CPT2 or VLCAD deficiency
[13,14]. Clinically, these deficiencies translate into a lim-
ited tolerance to metabolic stress conditions such as exer-
cise, fasting, or exposure to cold, which can trigger severe
muscular manifestations in CPT2 or VLCAD-deficient
patients [15]. In the past years, we explored therapeutic
approaches aimed at stimulating the production of mu-
tated enzyme [15,16]. Based on available literature data,
RSV was the only dietary component eventually capable
to induce stimulation of mitochondrial ß-oxidation, atleast after chronic in vivo administration in mice. This
led us to test the effects of RSV in ß-oxidation deficient
fibroblasts, and these initial studies established that ex-
posure to RSV (75 μM) could normalize FAO capacities
in patients cells with the muscular form of CPT2 or
VLCAD deficiency [17].
Data on the therapeutic potential of RSV in human
are still limited, but it is now admitted that RSV could
be used safely at a dosage ranging from a few milligrams
up to 1 gram per day [3,18]. Following ingestion, trans-
RSV, the most abundant natural RSV isomer, is quickly
absorbed and metabolized, and converted into a variety
of metabolites or conjugated forms, whose levels reach
up to 20-fold those of the parent molecule [18-20]. This
feeds the debate on the relevance of ex vivo observations
performed in cells treated with high concentrations of
trans-RSV [3,20,21]. On the other hand, the wide poten-
tial of this natural compound, its low price, and its ex-
cellent tolerance in humans, are strong incentives to
further characterize its effects, especially for possible ap-
plications in diseases with few treatments to date, such
as CPT2 or VLCAD deficiency.
When considering possible effects of RSV, both in vivo
or at the cell level, a large number of parameters could be
involved, many of which have little, or not, been character-
ized. For example, possible effects are primarily expected
to depend on the uptake of RSV by various tissues or cell
types, but the kinetics of RSV influx/efflux have been stud-
ied only in few instances [22,23]. Another important issue
is to determine if some cell culture system components
might affect RSV availability, and hence cellular response.
Considering the limited bioavailability of RSV, it also ap-
pears essential to characterize the cell responsiveness to
low, rather than to saturating, concentrations of RSV. Fi-
nally pharmacokinetics data raise questions about the role
of RSV metabolites, which quickly accumulate after RSV
ingestion, in mediating the effects of their parent molecule
[24]. In particular, there are no data on possible effects of
RSV metabolites on energy metabolism.
Accordingly, the first aim of the present study was to
perform pharmacological characterization of RSV effects
on FAO in cultured patient cells, with special focus on
analysis of RSV uptake and on the metabolic effects of
low RSV concentrations. In parallel, we analyzed possible
mitochondrial effects of the main RSV metabolites iden-
tified in human, which had never been evaluated so far.
Finally, we also tested metabolic effects of other natur-
ally occurring stilbenes commonly found in association
with RSV in plants and food.
Methods
Human fibroblasts and cell treatments
CPT2-deficient, VLCAD-deficient, or control human
skin fibroblasts used in this study have been described
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Table 1. Under standard conditions, fibroblasts were
grown in complete Ham’s F10 medium (Invitrogen) with
glutamine, 12% fetal calf serum (FCS), 100 U/ml penicil-
lin, and 0,1 mg/ml streptomycin. In some experiments
the FCS was reduced to 3%. This low serum value was
chosen because it allowed normal fibroblasts growth, in
contrast to serum-free media that results in blocking cell
proliferation. For treatment, the medium was removed
and replaced with fresh medium containing the various
compounds to be tested. These included RSV (Cayman
Chemical company, USA), or one of the following com-
pounds: cis-RSV (Cayman Chemical company, USA),
piceid (Art Molecule, France), RSV-3-O-D-glucuronide
(Art Molecule, France), RSV-4-O-D-glucuronide (Bertin
Pharma, France), RSV-3-O-sulfate (Art Molecule, France),
dihydroRSV (Art Molecule, France). Stock solutions of
these compounds were prepared in DMSO and protected
from light, and controls received equivalent amounts of
DMSO (≤0.05%).
Fatty acid oxidation measurements
Fatty acid oxidation (FAO) was measured by the produc-
tion of 3H2O from (9,10-
3H) palmitate, as described pre-
viously [25]. Briefly, after removal of cell culture
medium, fibroblasts seeded in 24-well plates were incu-
bated in 200 μl/well of PBS buffer containing 125 μM
tritiated palmitate + 1 mM carnitine, for 2 hours at 37°C.
After incubation, the mixture was removed and de-
proteinized, 3H2O was collected on ion-exchange resin,
and the eluate was counted by liquid scintillation. The
FAO values were expressed relative to protein content
determined by the Lowry method.
Acylcarnitine analysis
The method used has been described previously [26].
Briefly, fibroblasts were cultured in complete Ham’s F10
medium containing 200 μM palmitate and 400 μM car-
nitine for 72 hours at 37°C. The culture medium was
collected, extracted, and analyzed for acylcarnitine con-
tent by electrospray MS-MS, using an API3000 triple
quadrupole mass spectrometer (Sciex, Applied Biosys-
tems, USA) detecting the precursors of an m/z ratio ofTable 1 Mutations of CPT2- or VLCAD-deficient patients
Patients Mutated gene Nucleotid
1 CPT2 c.338C > T
2 CPT2 c.338C > T
3 VLCAD c.1144A > C
4 VLCAD c.848 T > C
5 VLCAD c.664G > A
The numbering of nucleotides starts at the first adenine of the translation initiation
The numbering of amino acids starts at the first methionine encoded by the transla85, by reference to added internal deuterated standards.
C16:0 acylcarnitines were quantified by reference to
standard curves.
Resveratrol uptake, efflux, and metabolism
Fibroblasts (0.7 × 105) were seeded on 24-well plates in
Ham’s F10 medium containing 12% FBS 24 h prior to
treatment with [3H]RSV (specific activity: 74 GBq/mmol,
Ge Health Care Life Science, Velizy-Villacoublay, France)
at various concentrations and for several time points at
37°C. At the end of the incubation periods, the labeled
medium was removed, and the cells were washed with
PBS and lysed with NaOH 1 M. Cell-associated radioactiv-
ity was counted in a liquid scintillation analyzer (Perkin
Elmer, Life Sciences Inc., Boston, MA). In parallel, cells
treated with unlabeled RSV for the same kinetic time
points, were used to measure protein content by the
Lowry method.
For efflux experiments, cells were loaded with radiola-
beled RSV (75 μM) for 1 h at 37°C (early maximal in-
corporation peak of RSV). After incubation, the labeled
medium was removed and replaced by standard culture
medium. Following this, the amount of RSV remaining
in the cells was determined at various time points by
counting cell-associated radioactivity.
For analysis of RSV metabolism, 106 fibroblasts were
treated by 75 μM RSV for 1 h and the medium was re-
placed by standard RSV-free medium. The presence of
RSV aglycone and RSV metabolites was then analyzed in
media and cell pellets at 0, 6 h, or 48 h after providing
RSV-free medium, by LC-MS, (Agilent Technologies), as
previously described [27].
Western blot analysis
Western blots were performed as described previously
[26]. The following antibodies were used: anti VLCAD
(kindly provided by Dr S. Yamagushi, Japan), anti CPT2
(kindly provided by Dr C. Prip-Buus, France), anti porin
(Abcam, Cambridge, UK), and anti ß-actin (Chemicon
International, Temecula, USA). The bands were scanned
by computerized densitometry (NIH Image J) and the
results were expressed as arbitrary units, normalized to
the amount of ß-actin.es change Amino acid change
c.371G > A S113L R124Q
c.112-113InsGC S113L S38Fs
c.1339G > A K382Q G447R
c.848 T > C V283A V283A
c.1512G > T G222R E504D
codon.
tion initiation codon.
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Data are the means ± SEM. Differences between groups
were analyzed by one-way analysis of variance (ANOVA)




































































































































Figure 1 Effects of 75 μM resveratrol for 48 h on ß-oxidation in
fibroblasts from control, CPT2-, or VCAD-deficient patients. A)
Quantification of palmitate oxidation flux. The results are means ± SEM of
at least three different experiments. In each experiment, the determinations
were performed in triplicate. Control values are from three different
healthy individuals. ***P < 0.001 compared with vehicle-treated
fibroblasts. B) Quantification of C16:0 acylcarnitine production by
tandem mass spectrometry. Results are expressed relative to cell
proteins and are means ± SEM. ***P < 0.001, when compared with
vehicle-treated cells, $$$ P < 0.001 compared with control fibroblasts.
Figure 2 Time-course of resveratrol uptake and efflux by
control and CPT2 (patient 1)- or VLCAD (patient 3)-deficient
fibroblasts. A) and B) Cells were incubated at 37°C with tritiated
RSV (75 μM) for the indicated times at 37°C. The uptake of labeled
RSV was assessed as described in Methods. Data points are means ±
SEM of at least three independent experiments each performed in
triplicate wells. C) Cells were loaded for 1 h with tritiated RSV
(75 μM, 37°C), the labeled medium was removed from the well and
replaced by fresh unlabeled medium to measure the remaining cell-
associated radioactivity, reflecting RSV efflux at the indicated time
points. The values represent means ± SEM relative to uptake value
observed after 1 h of treatment (maximal RSV uptake by cells). Data
are from a representative experiment among two and each point
represents the mean of three determinations on separate wells.
Table 2 Concentration of resveratrol and its metabolites in cell culture medium
Supernatant concentration (μM)
Control Patient 1 Patient 3
Species EFFLUX (hrs) 0 6 48 0 6 48 0 6 48
Resveratrol 65.24 ± 7.14 5.49 ± 0.41 3.23 ± 0.58 61.07 ± 5.81 3.12 ± 0.81 3.09 ± 0.07 70.34 ± 0.73 4.20 ± 0.33 3.59 ± 0.74
Resveratrol-3-0-sulfate 0.02 ± 0.01 0.70 ± 0.09 4.01 ± 0.60 0.02 ± 0.004 0.40 ± 0.12 3.68 ± 0.04 0.02 ± 0.002 0.33 ± 0.03 2.37 ± 0.47
Resveratrol-3-0-glucuronide nd. nd. nd. nd. nd. nd. nd. nd. nd.
Resveratrol-4′-0-glucuronide nd. nd. nd. nd. nd. nd. nd. nd. nd.
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Exposure to trans-resveratrol can correct FAO deficiency
in patient cells
As shown in Figure 1A, fibroblasts from patients with
CPT2 or VLCAD deficiency typically exhibited markedly
reduced palmitate oxidation capacities (from 1.3 to
3.3 nmol/h/mg), compared to control fibroblasts (5.2 ±
0.2 nmol/h/mg). Under standard culture conditions, treat-
ment of fibroblasts by 75 μM RSV for two days led to max-
imal increases in palmitate oxidation in control (+45%) and
patient cells (from +83 to +252%). This resulted in the res-
toration of normal FAO rates in all the CPT2- or VLCAD-
deficient treated cells. The beneficial effect of RSV on FAO
was further investigated by analysis of acylcarnitine profiles.
As seen in Figure 1B, abnormal accumulation of long-
chain acylcarnitines was observed in untreated CPT2 or
VLCAD deficient fibroblasts, and a 3-day treatment with
75 μM RSV normalized the C16:0 acylcarnitine production.
Time course of resveratrol uptake in cultured fibroblasts
Under standard culture conditions, RSV (75 μM) was
rapidly incorporated into control, CPT2- and VLCAD-
deficient fibroblasts at 37°C, and its uptake was only dis-
cretely modified by low temperature (4°C; data not
shown). In short-term experiments, uptake values in con-
trol cells reached about 90% of their maximal value at
12 minutes and remained stable up to 120 minutes,
around 7000 pmol/mg proteins (Figure 2A). Interestingly,
similar uptake levels were still observed after a 48 or 72 h
exposure to RSV (Figure 2B). Patient 1 and patient 3 up-
take values were in the range of 3000 to 6000 pmol/mgTable 3 Concentration of resveratrol and its metabolites in fi
Cellular co
Control
Species EFFLUX (hrs) 0 6 48
Resveratrol 14.96 ± 2.12 1.30 ± 0.21 0.83 ± 0.06 22.06
Resveratrol-3-0-sulfate 0.15 ± 0.04 0.18 ± 0.02 0.35 ± 0.03 0.18
Resveratrol-3-0-glucuronide nd. nd. nd.
Resveratrol-4′-0-glucuronide nd. nd. nd.
n.d., Not detected.proteins between 12 and 120 minutes. In long-term exper-
iments, values of RSV uptake in patient 1 generally
remained lower than in control fibroblasts, In contrast,
RSV accumulation in patient 3 fibroblasts transiently rose
between 6 and 24 hours, and went back to control values
at 48 and 72 hours. Thus, CPT2-deficient cells tended to
incorporate less RSV than control or VLCAD-deficient
cells (Figure 2B). However, RSV incorporation in long-
term experiments remained at high levels in the three fi-
broblasts cell lines, representing more than 50% of their
maximal uptake value (Figure 2B), and indicating a
steady-state between RSV influx and efflux rates.
Efflux and metabolism of resveratrol in control and
patient fibroblasts
After exposure to 75 μM RSV for one hour, measurements
of efflux showed that RSV was rapidly released in the
extracellular medium, and 60% to 80% of intracellular
RSV content was lost after 2 h (Figure 2C). In parallel, no
detectable production of RSV glucuro- conjugates, and a
very low level of RSV-3-O-sulfate, were measured (Table 2
and Table 3).
Resveratrol uptake is negatively regulated by fetal calf
serum
As shown in Figure 3, increasing fetal calf serum (FCS)
content from 0.5 to 12% in the culture medium resulted
in a marked decrease of RSV uptake values, both in con-
trol and in patient fibroblasts. This clearly suggests that
some FCS components might reduce RSV bioavailability
in the cell culture system.broblasts
ncentration (nmoles/mg of proteins)
Patient 1 Patient 3
0 6 48 0 6 48
± 1.95 1.29 ± 0.11 0.74 ± 0.06 20.58 ± 1.40 1.30 ± 0.17 0.89 ± 0.15
± 0.05 0.18 ± 0.02 0.27 ± 0.02 0.08 ± 0.01 0.10 ± 0.01 0.17 ± 0.02
nd. nd. nd. nd. nd. nd.
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Figure 3 Effect of fetal calf serum (FCS) on resveratrol uptake by control and CPT2- or VLCAD-deficient fibroblasts. RSV uptake was
examined by incubating control or patients’ fibroblasts with [3H]-RSV (75 μM) in serum-free medium or in medium supplemented with increasing
FCS content for 1 h at 37°C. Data are means ± SEM of three determinations on separate wells. *P < 0.05, ***P < 0.001 vs. the previous column.
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FCS content of culture medium
We then compared the responses of control or patient
cells to a 48 h treatment with 20 or 75 μM RSV in culture
medium containing either 12% or 3% FCS. In the absence
of RSV, western-blot experiments (Figure 4A and B) re-
vealed a marked CPT2 or VLCAD protein deficiency in
patient 1 and patient 4, respectively compared to control
fibroblasts. Treatment with 75 μM RSV in 12% FCS
medium resulted in a significant induction of CPT2
(Figure 4A) and VLCAD (Figure 4B) proteins in control
and in patients’ cells. By contrast, treatment with 20 μM
RSV in 12% FCS induced either modest increases or no
changes in CPT2 (Figure 4A) and VLCAD (Figure 4B)
proteins levels. Noticeably, for both RSV concentrations
tested, the levels of CPT2 and VLCAD proteins in control
and patient fibroblasts were significantly augmented when
treatment was performed in 3% FCS medium.
We then measured FAO capacities in control, and in
patient fibroblasts exposed to 10, 20, 37.5, or 75 μM
RSV in culture medium containing 12% or 3% FCS
(Figure 5). Control cells treated in 12% FCS exhibited
modest increases in FAO unless RSV reached 37.5 μM,
when half-maximal FAO stimulation was observed (p < 0.01)
(Figure 5A). When control fibroblasts were treated in
3% FCS medium, there was an increase in the slope of
FAO dose–response curve, indicating an amplified re-
sponse to RSV. Vehicle-treated patient cells exhibited
more pronounced FAO deficiencies when grown in 3%
FCS compared to 12% FCS medium (Figure 5B and C).
After treatment with RSV in 3% FCS medium, patient
cells exhibited a shift of dose–response curves towards
higher values, compared to those observed in 12% FCS
medium. Noticeably, in patient cells grown in 3% FCS
medium, robust responses were already observed at
10 μM RSV, which triggered a +228% and +115% in-
crease in FAO in VLCAD and CPT2-deficient fibro-
blasts, respectively, whereas, no response was observed
in 12% FCS.We then compared incorporation levels of 20 μM RSV
in 12% and 3% FCS medium (Figure 6A and B). Between
0 and 2 hours, control and patient cells accumulated lar-
ger amounts of RSV when treated in culture medium
containing 3% (about 1000 pmoles/mg proteins), com-
pared to 12% (about 750 pmol/mg proteins) FCS. At 24
and 48 hours, cellular uptake values reached 3000–4000
pmol/mg proteins in 3% FCS, i.e. more than twofold
those observed in 12% FCS.
Effect of resveratrol metabolites and of other stilbenes in
FAO-deficient patient cells
We evaluated the effects of compounds structurally re-
lated to RSV, and of RSV metabolites. Two of them are
stilbene compounds naturally found in association with
RSV in foods, namely cis-RSV and trans-piceid [28]. The
four others are major human metabolites i.e. RSV-3-O-
and −4-O-glucuronide, RSV-3-O-sulfate, and dihydro-
RSV. Cells were treated with 75 μM of each compound
in 12% FCS medium for 48 h. Initial screening was per-
formed in one control, one CPT2-deficient and one
VLCAD-deficient cell line (Figure 7A). In control fibro-
blasts, exposure to cis-RSV or to piceid induced similar
changes (+25%) in FAO. Treatment with these com-
pounds resulted in a more pronounced increase in FAO
in CPT2- (+121 to +125%, respectively) and in VLCAD-
deficient fibroblasts (+30 to +50%, respectively). Treat-
ment with each of four RSV metabolites tested generally
resulted in modest changes (<15%) in FAO capacities
in control fibroblasts. In patient cells, exposure to 3- or
4-glucuro-RSV led to moderate or no increase in FAO.
In contrast, treatment with dihydro-RSV augmented
FAO by 130 or 52% in CPT2 or VLCAD-deficient fibro-
blasts, respectively. The effects of these compounds were
further analyzed in additional control, and deficient
fibroblasts (Figure 7B). Altogether, these experiments
established that exposure to cis-RSV, to piceid, or to
dihydro-RSV triggered significant increases in FAO in
control and patient cells. Consistent with this, cis-RSV,
BVLCAD
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Figure 4 Effects of medium FCS content on the response to
RSV. Cells were treated in 3% or 12% FCS medium with 20 or 75 μM
RSV, or vehicle, for 48 h prior to protein extraction and western
blot analysis. A) CPT2 protein levels in control or CPT2-deficient
fibroblasts. B) VLCAD protein levels in control or VLCAD-deficient
fibroblasts. Histograms of protein amounts normalized to ß-actin are
shown, as well as representative western-blots. Values are means ±
SEM of three westerns. Control values are from three different
individuals. *P < 0.05, **P < 0.01, ***P < 0.001 when compared
with vehicle-treated cells, $ P < 0.05, $$P < 0.01, $$$ P < 0.001























































































































Figure 5 Effects of resveratrol on FAO flux according to the
FCS content in the culture medium, in control and FAO-
deficient fibroblasts. Dose–response studies of RSV effects on
tritiated palmitate oxidation rates in A) controls B) CPT2- or C)
VLCAD deficient patients’ fibroblasts. Cells were treated for 48 h.
Control values are from three different individuals. The results are
means ± SEM of at least three different experiments. In each experiment,
the determinations were performed in triplicate. ***P < 0.001 when
compared with cells treated in 12% FCS medium.
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of CPT2 (Figure 8A) and VLCAD (Figure 8B) proteins
levels, accounting for the stimulatory effects of these com-
pounds on FAO capacities.
Resveratrol metabolites and other stilbenes induce
mitochondrial biogenesis
The effects of RSV, cis-RSV, piceid and dihydro-RSV on
mitochondrial biogenesis was assessed by western blot
analysis of two mitochondrial proteins generally admit-
ted to reflect mitochondrial mass. Porin is a voltage
dependent anion selective channel located in the outer
mitochondrial membrane and Tfam, is the mitochon-

































































































































































Figure 6 Time-course of resveratrol (20 μM) uptake by control and FAO-deficient fibroblasts according to the FCS content in the cul-
ture medium. RSV uptake was examined by incubating fibroblasts with [3H]-RSV (20 μM) in medium containing A) 12% or B) 3% FBS at 37°C for
the indicated times. The values represent means ± SEM of two independent experiments each performed in triplicate wells.
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blot analysis revealed a general stimulation of porin
and Tfam protein expression in response to RSV, cis-
RSV, piceid and dihydro-RSV, i.e. to all the compounds
that were found to induce increases of FAO capacities
(Figure 9).
Discussion
The present study shows that exposure of CPT2- or
VLCAD-deficient fibroblasts to RSV could induce up-
regulation of mutated enzyme level, possibly leading to
restore normal FAO capacities. This is in line with previ-
ous studies [17], and with other data suggesting that
FAO is one of the main mitochondrial pathways im-
pacted by RSV [5,8]. To gain further insights into its
metabolic effects, we characterized the kinetics of RSV
uptake. Control and FAO-deficient fibroblasts rapidly
accumulated RSV, and, despite variability in the kinetics
of RSV uptake between the cell lines, generally main-
tained high intracellular levels when chronically exposed
to RSV. RSV uptake was modestly affected by low
temperature suggesting that incorporation mainly pro-
ceeded via passive diffusion. In hepatoma cells, RSV
accumulates both by passive diffusion and by carrier-mediated processes, however its content rapidly de-
creases after reaching its maximal value [23], in part be-
cause hepatoma cells metabolize RSV [30]. In contrast,
our results indicate almost no detectable production of
RSV metabolites by human fibroblasts, consistent with
literature data showing that xenobiotic metabolism is ex-
tremely low in human fibroblasts [31-34].
Despite the large number of studies dealing with RSV
effects in numerous cell types, there are few data on in-
trinsic factors that could affect the response to RSV in
cultured cells. In this regards, our results show that
intracellular RSV levels were significantly higher after
treatment in 3% versus 12% FCS medium. In line with
this, induction of CPT2 and VLCAD proteins, and
stimulation of FAO capacities by RSV were markedly en-
hanced using low FCS medium. Thus, RSV uptake, and
hence cell response to RSV, appeared negatively regu-
lated by some FCS components. In our cultured fibro-
blasts, we found that addition of bovine serum albumin
in serum-free culture medium already induced a marked
dose-dependent decrease in RSV uptake (data not
shown). Accordingly, negative effects of FCS on RSV up-
take might be partly attributed to the high serum albu-
























































































Figure 7 Effects of natural stilbene compounds and RSV metabolites on FAO flux in control and patient fibroblasts. Cells were treated
with 75 μM of each compound for 48 h. A) compared effects of eight compounds in controls, CPT2- or VLCAD-deficient fibroblasts. B) compared
effects of the most effective compounds in controls, CPT2- or VLCAD-deficient fibroblasts. Histograms are means ± SEM of at least three different
experiments. Control values are from three different individuals. ***P < 0.001 compared with vehicle-treated fibroblasts.
Aires et al. Orphanet Journal of Rare Diseases 2014, 9:79 Page 9 of 13
http://www.ojrd.com/content/9/1/79suggest that albumin could behave as a RSV binding pro-
tein [22,35]. Overall, these observations might account for
the high RSV concentrations commonly needed to trigger
metabolic responses in cultured cells. Last, in vivo data in-
dicate that a significant fraction of plasma RSV is bound
to human serum albumin [19,20,36]. This protein-bound
circulating RSV might serve as a reservoir to enhance
in vivo half-life of this compound, by limiting its absorp-
tion and metabolism [36].
Exposure to RSV was reported to enhance FAO cap-
acities in 3 T3 adipocyte [8] and in C2C12 muscle
cells [5,9]. RSV might also stimulate mitochondrial ß-
oxidation in vivo, as shown in a rat model of heart
failure [37], or in rats submitted to endurance training
[6]. Furthermore, a recent clinical trial in obese men re-
ceiving low doses of RSV (150 mg/day) established benefi-
cial effects on energy metabolism, and suggested a preferred
use of fatty acids as energy substrates under treatment
by RSV [38].
The natural sources of RSV often associate a variety of
other stilbenes. Thus, trans-piceid and cis-RSV are
among the most abundant stilbenes present in foods, to-
gether with trans-RSV [28]. However, there were no dataon possible effects of these compounds on energy me-
tabolism. Interestingly, the present study indicates that
cell exposure to cis-RSV, often considered as a by-
product of trans-RSV, or to piceid, which represents the
major form of RSV in plants, triggered a significant in-
crease in ß-oxidation capacities in control and patient
fibroblasts. Following ingestion in human, RSV is metab-
olized into glucuro- or sulfo-conjugates in the liver, and
converted by intestinal microbiota into di-hydro RSV,
one of the most abundant circulating RSV metabolites
[18-20]. However, possible effects of these compounds
on mitochondrial functions had never been investigated.
Our results indicate that the 3-glucuronide derivative
exhibited low stimulatory effects on FAO, whereas the
4-glucuro and 3-sulfo were ineffective. In contrast,
dihydro-RSV appeared as a potent inducer of FAO cap-
acities in patient fibroblasts. Overall, FAO assays in pa-
tient fibroblasts provide a sensitive approach to screen
compounds potentially capable to induce stimulation of
ß-oxidation in human cells [16]. The present study iden-
tifies several compounds that had not yet been described
as regulating FAO capacities, including two natural stil-















































































Figure 8 Effects of natural stilbene compounds and RSV metabolites in control and patient fibroblasts. Cells were treated with 75 μM of
each compound for 48 h. A) changes in CPT2 protein levels in control and CPT2-deficient fibroblasts. B) changes in VLCAD protein levels in
control and VLCAD-deficient fibroblasts. Histograms are means ± SEM of three different experiments. Control values are from three different
individuals. *P < 0.05, **P < 0.01, ***P < 0.001 when compared with vehicle-treated cells.
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http://www.ojrd.com/content/9/1/79and piceid [28] and one RSV metabolite i.e. dihydro-
RSV. Interestingly, consumption of foodstuffs naturally
rich in RSV will often lead to supply the three com-
pounds to the organism, in addition to RSV.
From a mechanistic point of view, several studies indi-
cate that RSV might stimulate mitochondrial biogenesis
both in vivo, in mice submitted to high fat diet [5] or ex-
ercise [39], and in vitro in various cells [4,40]. In this
study, we show that RSV and other related compounds
triggered a stimulation of mitochondrial biogenesis that
might underlie the increases in ß-oxidation flux. This is
in line with our previous studies in human fibroblastsshowing that RSV enhanced the protein level of PGC-1α,
a master regulator of mitochondrial biogenesis [17,41].
Conclusions
Altogether, our data show that human fibroblasts in pri-
mary culture stably incorporate RSV over a 48 h period,
and do not produce significant levels of resveratrol me-
tabolites. Exposure to RSV induced a marked increase in
mitochondrial ß-oxidation flux, leading to the correction
of FAO capacities in patients’ cells with the myopathic
form of VLCAD or CPT2 deficiency. Pharmacological
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Figure 9 Effects of natural stilbene compounds and RSV metabolites on porin and Tfam protein levels in control and patient fibroblasts.
Cells were treated with 75 μM of each compound for 48 h. Histograms are means ± SEM of three different experiments. Control values are from three
different individuals. *P < 0.05, **P < 0.01, ***P < 0.001 when compared with vehicle-treated cells.
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http://www.ojrd.com/content/9/1/79increased expression of mutant CPT2 or VLCAD pro-
teins, as previously observed using bezafibrate. Increas-
ing the level of misfolded proteins might theoretically
induce secondary toxic effects, and in particular cellular
oxidative stress [42]. In this regards, RSV, a known anti-
oxidant compound, might have dual beneficial effects,
possibly restoring FAO while counteracting oxidative
stress in the treated cells. This study also brings the first
data on mitochondrial effects of other natural com-
pounds of the stilbene family, such as piceid and cis-
RSV, which were both found to act as activators of
mitochondrial FAO in control and in FAO-deficient fi-
broblasts. Similar approaches allowed screening RSV
metabolites for their mitochondrial effects, and revealed
that dihydro-RSV, one of the most abundant circulating
resveratrol metabolites in human, could trigger a marked
stimulation of FAO in deficient cells. Accordingly, this
study suggests that RSV, in combination with its metab-
olites and with other naturally occurring stilbenes, might
positively impact mitochondrial functions in human
cells, possibly leading to the correction of FAO capaci-
ties in deficient cells. Accordingly, RSV and some related
molecules might, at least in some cases, evolve from thestatus of micronutrients to that of natural drugs. It
should be kept in mind, however that results from pre-
clinical studies such as those obtained in the present
study cannot be extrapolated to the in vivo situation,
and will ultimately require to be tested in clinical trials
in order to really evaluate the potential of RSV in these
rare diseases.
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